Purevax RCP FeLV


Vaccine against feline viral rhinotracheitis, feline calicivirosis, feline panleucopenia and feline leukaemia

This medicine is authorised for use in the European Union.


This is a summary of the European public assessment report. Its purpose is to explain how the assessment done by the Committee for Medicinal Products for Veterinary Use (CVMP) on the basis of the documentation provided, led to the recommendations on the conditions of use.

This document cannot replace a face-to-face discussion with your veterinarian. If you need more information about your animal’s medical condition or treatment, contact your veterinarian. If you want more information on the basis of the CVMP recommendations, read the scientific discussion (also part of the EPAR).

This EPAR was last updated on 01/12/2020

Authorisation details

Product details
Purevax RCP FeLV
Agency product number
Active substance
Attenuated feline rhinotracheitis herpesvirus (FHV F2 strain), inactivated feline Calicivirosis antigens (FCV 431 and G1 strains), attenuated feline panleucopenia virus (PLI IV), FeLV recombinant canarypox virus (vCP97)
International non-proprietary name (INN) or common name
Vaccine against feline viral rhinotracheitis, feline calicivirosis, feline panleucopenia and feline leukaemia
Anatomical therapeutic chemical veterinary (ATCvet) codes
Publication details
Marketing-authorisation holder
Boehringer Ingelheim Vetmedica GmbH
Date of issue of marketing authorisation valid throughout the European Union
Contact address

Binger Strasse 173
55216 Ingelheim am Rhein

Product information

14/10/2020 Purevax RCP FeLV - EMEA/V/C/000089 - WS/1733/G


Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

Immunologicals for felidae

Therapeutic indication

Active immunisation of cats aged 8 weeks and older:

  • against feline viral rhinotracheitis to reduce clinical signs;
  • against calicivirus infection to reduce clinical signs and excretion;
  • against feline panleucopenia to prevent mortality and clinical signs;
  • against leukaemia to prevent persistent viraemia and clinical signs of the related disease.

Onsets of immunity have been demonstrated 1 week after primary vaccination course for rhinotracheitis, calicivirus and panleucopenia components, and 2 weeks after primary vaccination course for feline leukaemia component.

The duration of immunity is one year after the last re-vaccination for the feline leukaemia component, and three years for the rhinotracheitis, calicivirosis and panleucopenia components.

Assessment history

How useful was this page?

Add your rating
1 rating
1 rating
1 rating